{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T19:47:02Z","timestamp":1768592822097,"version":"3.49.0"},"reference-count":54,"publisher":"BMJ","issue":"19","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:p>Improved and durable control of hypertension is a global priority for healthcare providers and policymakers. There are several lifestyle measures that are proven to result in improved blood pressure (BP) control. Moreover, there is incontrovertible evidence from large scale randomised controlled trials (RCTs) that antihypertensive drugs lower BP safely and effectively in the long-term resulting in substantial reduction in cardiovascular morbidity and mortality. Importantly, however, evidence is accumulating to suggest that patients neither sustain long-term healthy behaviours nor adhere to lifelong drug treatment regimens and thus alternative measures to control hypertension warrant further investigation. Endovascular renal denervation (RDN) appears to hold some promise as a non-pharmacological approach to lowering BP and achieves renal sympathectomy using either radiofrequency energy or ultrasound-based approaches. This treatment modality has been evaluated in clinical trials in humans since 2009 but initial studies were compromised by being non-randomised, without sham control and small in size. Subsequently, clinical trial design and rigour of execution has been greatly improved resulting in recent sham-controlled RCTs that demonstrate short-term reduction in ambulatory BP without any significant safety concerns in both medication-na\u00efve and medication-treated hypertensive patients. Despite this, the joint UK societies still feel that further evaluation of this therapy is warranted and that RDN should not be offered to patients outside of the context of clinical trials. This document reviews the updated evidence since our last consensus statement from 2014 and provides a research agenda for future clinical studies.<\/jats:p>","DOI":"10.1136\/heartjnl-2019-315098","type":"journal-article","created":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T21:15:24Z","timestamp":1562793324000},"page":"1456-1463","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":26,"title":["Joint UK societies\u2019 2019 consensus statement on renal denervation"],"prefix":"10.1136","volume":"105","clinical-trial-number":[{"clinical-trial-number":"nct02649426","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02392351","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1122-948X","authenticated-orcid":false,"given":"Melvin D","family":"Lobo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew S P","family":"Sharp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikas","family":"Kapil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A","family":"de Belder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trevor","family":"Cleveland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clare","family":"Bent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Indranil","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terry","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Matson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manish","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco P","family":"Cappuccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,7,10]]},"reference":[{"key":"2020050721474749000_105.19.1456.1"},{"key":"2020050721474749000_105.19.1456.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.07.008"},{"key":"2020050721474749000_105.19.1456.3","first-page":"1101","article-title":"Interventional procedures and future drug therapy for hypertension","volume":"38","author":"Lobo","year":"2017","journal-title":"Eur Heart J"},{"key":"2020050721474749000_105.19.1456.4","unstructured":"Caulfield M , de Belder M , Cleveland T , et al . Joint UK Societies\u2019 Consensus Summary Statement on Renal Denervation for Resistant Hypertension. 2011 http:\/\/www.bhsoc.org\/docs\/Joint-UK-Societies-Summary-on-Renal-Denervation.pdf."},{"key":"2020050721474749000_105.19.1456.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62039-9"},{"key":"2020050721474749000_105.19.1456.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60566-3"},{"key":"2020050721474749000_105.19.1456.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402670"},{"key":"2020050721474749000_105.19.1456.8","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2014-307029"},{"key":"2020050721474749000_105.19.1456.9","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv192"},{"key":"2020050721474749000_105.19.1456.10","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/eurheartj\/ehx215","article-title":"Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future","volume":"38","author":"Mahfoud","year":"2017","journal-title":"Eur Heart J"},{"key":"2020050721474749000_105.19.1456.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.03.059"},{"key":"2020050721474749000_105.19.1456.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.08.018"},{"key":"2020050721474749000_105.19.1456.13","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa3236"},{"key":"2020050721474749000_105.19.1456.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.07.937"},{"key":"2020050721474749000_105.19.1456.15","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ahj.2015.08.021","article-title":"The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications","volume":"171","author":"Kandzari","year":"2016","journal-title":"Am Heart J"},{"key":"2020050721474749000_105.19.1456.16","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(17)32281-X","article-title":"Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial","volume":"390","author":"Townsend","year":"2017","journal-title":"Lancet"},{"key":"2020050721474749000_105.19.1456.17","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19960715)15:13<1421::AID-SIM266>3.0.CO;2-H"},{"key":"2020050721474749000_105.19.1456.18","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1016\/S0140-6736(18)30951-6","article-title":"Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial","volume":"391","author":"Kandzari","year":"2018","journal-title":"Lancet"},{"key":"2020050721474749000_105.19.1456.19","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ahj.2017.09.006","article-title":"A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: The RADIANCE-HTN and REQUIRE clinical study designs","volume":"195","author":"Mauri","year":"2018","journal-title":"Am Heart J"},{"key":"2020050721474749000_105.19.1456.20","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/S0140-6736(18)31082-1","article-title":"Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial","volume":"391","author":"Azizi","year":"2018","journal-title":"Lancet"},{"key":"2020050721474749000_105.19.1456.21","unstructured":"Weber M , Kirtane AJ , Weir MR , et al . Six Month Results of the REDUCE HTN:REINFORCE Study of Renal Denervation for the Treatment of Hypertension. TCT2018. San Diego, USA, 2018."},{"key":"2020050721474749000_105.19.1456.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61942-5"},{"key":"2020050721474749000_105.19.1456.23","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.022922"},{"key":"2020050721474749000_105.19.1456.24","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1161\/CIRCULATIONAHA.118.037654","article-title":"A Three-Arm Randomized Trial of Different Renal Denervation Devices and Techniques in Patients With Resistant Hypertension (RADIOSOUND-HTN)","volume":"139","author":"Fengler","year":"2019","journal-title":"Circulation"},{"key":"2020050721474749000_105.19.1456.25","doi-asserted-by":"publisher","DOI":"10.4244\/EIJV9I4A78"},{"key":"2020050721474749000_105.19.1456.26","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.114.05010"},{"key":"2020050721474749000_105.19.1456.27","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1097\/HJH.0000000000001085","article-title":"Renal denervation reduces office and ambulatory heart rate in patients with uncontrolled hypertension: 12-month outcomes from the global SYMPLICITY registry","volume":"34","author":"B\u00f6hm","year":"2016","journal-title":"J Hypertens"},{"key":"2020050721474749000_105.19.1456.28","first-page":"ehw325","article-title":"Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry","volume":"38","author":"Mahfoud","year":"2017","journal-title":"Eur Heart J"},{"key":"2020050721474749000_105.19.1456.29","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/jch.13007","article-title":"Improvement in health-related quality of life after renal sympathetic denervation in real-world hypertensive patients: 12-month outcomes in the Global SYMPLICITY Registry","volume":"19","author":"Kindermann","year":"2017","journal-title":"J Clin Hypertens"},{"key":"2020050721474749000_105.19.1456.30","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-015-0959-4"},{"key":"2020050721474749000_105.19.1456.31","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/HJH.0000000000001517","article-title":"Renal sympathetic denervation in Sweden: a report from the Swedish registry for renal denervation","volume":"36","author":"V\u00f6lz","year":"2018","journal-title":"J Hypertens"},{"key":"2020050721474749000_105.19.1456.32","unstructured":"FaD A . Circulatory system devices panel meeting: clinical evaluation of anti-hypertensive devices. 2018."},{"key":"2020050721474749000_105.19.1456.33","unstructured":"Excellence NIfHaC. Percutaneous transluminal radiofrequency sympathetic denervation of the renal artery for resistant hypertension. 2012."},{"key":"2020050721474749000_105.19.1456.34","unstructured":"England N. Clinical Commissioning Policy: Renal denervation for resistant hypertension. 2016."},{"key":"2020050721474749000_105.19.1456.35","first-page":"603","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"2018","author":"Williams","year":"2018","journal-title":"European heart journal"},{"key":"2020050721474749000_105.19.1456.36","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1097\/HJH.0000000000001858","article-title":"European Society of Hypertension position paper on renal denervation 2018","volume":"36","author":"Schmieder","year":"2018","journal-title":"J Hypertens"},{"key":"2020050721474749000_105.19.1456.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.10.051"},{"key":"2020050721474749000_105.19.1456.38","first-page":"e21","volume":"36","author":"Schmieder","year":"2018","journal-title":"J Hypertens"},{"key":"2020050721474749000_105.19.1456.39","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1097\/HJH.0000000000000977","article-title":"Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial","volume":"34","author":"Mathiassen","year":"2016","journal-title":"J Hypertens"},{"key":"2020050721474749000_105.19.1456.40","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.115.05283"},{"key":"2020050721474749000_105.19.1456.41","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1161\/HYPERTENSIONAHA.118.11180","article-title":"Renal denervation in resistant hypertension and obstructive sleep apnea: randomized proof-of-concept Phase II Trial","volume":"72","author":"Warchol-Celinska","year":"2018","journal-title":"Hypertension"},{"key":"2020050721474749000_105.19.1456.42","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/08037051.2017.1320939","article-title":"Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension","volume":"26","author":"Jacobs","year":"2017","journal-title":"Blood Press"},{"key":"2020050721474749000_105.19.1456.43","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1161\/HYPERTENSIONAHA.116.08818","article-title":"Impact of medication adherence on the effect of renal denervation: the SYMPATHY Trial","volume":"69","author":"de Jager","year":"2017","journal-title":"Hypertension"},{"key":"2020050721474749000_105.19.1456.44","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1097\/HJH.0000000000001025","article-title":"Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study - a randomized controlled trial","volume":"34","author":"Oliveras","year":"2016","journal-title":"J Hypertens"},{"key":"2020050721474749000_105.19.1456.45","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.114.04019"},{"key":"2020050721474749000_105.19.1456.46","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-15-0150"},{"key":"2020050721474749000_105.19.1456.47","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.114.03246"},{"key":"2020050721474749000_105.19.1456.48","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1161\/HYPERTENSIONAHA.118.12250","article-title":"Sustained decrease in blood pressure and reduced anatomical and functional reinnervation of renal nerves in hypertensive sheep 30 months after catheter-based renal denervation","volume":"73","author":"Singh","year":"2019","journal-title":"Hypertension"},{"key":"2020050721474749000_105.19.1456.49","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11906-018-0838-2","article-title":"Selective vs. Global Renal Denervation: a case for less is more","volume":"20","author":"Fudim","year":"2018","journal-title":"Curr Hypertens Rep"},{"key":"2020050721474749000_105.19.1456.50","doi-asserted-by":"crossref","first-page":"e1334","DOI":"10.4244\/EIJ-D-18-00536","article-title":"Safety and performance of diagnostic electrical mapping of renal nerves in hypertensive patients","volume":"14","author":"Tsioufis","year":"2018","journal-title":"EuroIntervention"},{"key":"2020050721474749000_105.19.1456.51","doi-asserted-by":"crossref","unstructured":"Saxena M , Shour T , Shah M , et al . Attenuation of Splanchnic Autotransfusion Following Noninvasive Ultrasound Renal Denervation: a novel marker of procedural success. J Am Heart Assoc 2018;7.doi:10.1161\/JAHA.118.009151","DOI":"10.1161\/JAHA.118.009151"},{"key":"2020050721474749000_105.19.1456.52","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.991869"},{"key":"2020050721474749000_105.19.1456.53","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu093"},{"key":"2020050721474749000_105.19.1456.54","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/jch.13193","article-title":"Renal denervation improves 24-hour central and peripheral blood pressures, arterial stiffness, and peripheral resistance","volume":"20","author":"Ott","year":"2018","journal-title":"J Clin Hypertens"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2019-315098","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T18:25:55Z","timestamp":1601058355000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2019-315098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,10]]},"references-count":54,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2019,9,12]]},"published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.1136\/heartjnl-2019-315098"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2019-315098","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,10]]}}}